Literature DB >> 30309751

The risk of Parkinson's disease in inflammatory bowel disease: A systematic review and meta-analysis.

Feng Zhu1, Chuling Li1, Jianfeng Gong2, Weiming Zhu2, Lili Gu3, Ning Li2.   

Abstract

BACKGROUND: Several studies have reported an increased prevalence of Parkinson disease (PD) amongst patients with inflammatory bowel disease (IBD) with conflicting results. We aimed to evaluate the risk of PD in the IBD population by conducting a meta-analysis (MA).
METHODS: A systematic review with MA of the existing literature was conducted. The main outcome of interest was the incidence of developing PD in patients previously diagnosed with IBD.
RESULTS: Four studies were included in this MA. The overall risk of PD in IBD was significantly higher than controls (RR 1.41, 95% c.i. 1.19-1.66). Crohn's disease had a 28% increased risk of PD and ulcerative colitis had a 30% increased risk of PD compared to controls (CD: RR 1.28, 95% c.i. 1.08-1.52, UC: RR 1.30, 95% c.i. 1.15-1.47).
CONCLUSION: The MA detected an increased risk of PD in the IBD population and CD/UC subgroup. These results merit further clinical validation in future studies.
Copyright © 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Co-occurrence; LRRK2; Population-based; Risk ratio

Mesh:

Year:  2018        PMID: 30309751     DOI: 10.1016/j.dld.2018.09.017

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  37 in total

Review 1.  Is Parkinson's disease a chronic low-grade inflammatory bowel disease?

Authors:  Malvyne Rolli-Derkinderen; Laurène Leclair-Visonneau; Arnaud Bourreille; Emmanuel Coron; Michel Neunlist; Pascal Derkinderen
Journal:  J Neurol       Date:  2019-04-12       Impact factor: 4.849

Review 2.  Review of Metabolomics-Based Biomarker Research for Parkinson's Disease.

Authors:  Xin Li; Xiaoying Fan; Hongtian Yang; Yufeng Liu
Journal:  Mol Neurobiol       Date:  2021-11-26       Impact factor: 5.590

Review 3.  The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic.

Authors:  Ai Huey Tan; Shen Yang Lim; Anthony E Lang
Journal:  Nat Rev Neurol       Date:  2022-06-24       Impact factor: 44.711

4.  The Risk of Developing Alzheimer's Disease and Parkinson's Disease in Patients with Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Marta Szandruk-Bender; Benita Wiatrak; Adam Szeląg
Journal:  J Clin Med       Date:  2022-06-27       Impact factor: 4.964

Review 5.  The Pathological Mechanism Between the Intestine and Brain in the Early Stage of Parkinson's Disease.

Authors:  Runing Yang; Ge Gao; Hui Yang
Journal:  Front Aging Neurosci       Date:  2022-06-24       Impact factor: 5.702

Review 6.  T Lymphocytes in Parkinson's Disease.

Authors:  Elena Contaldi; Luca Magistrelli; Cristoforo Comi
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

7.  Characterization of Gastrointestinal Symptom Type and Severity in Parkinson's Disease: A Case-Control Study in an Australian Cohort.

Authors:  Jade E Kenna; Megan C Bakeberg; Anastazja M Gorecki; Alfred Chin Yen Tay; Samantha Winter; Frank L Mastaglia; Ryan S Anderton
Journal:  Mov Disord Clin Pract       Date:  2021-01-05

8.  The gut microbiota and nervous system: Age-defined and age-defying.

Authors:  Annelise A Madison; Janice K Kiecolt-Glaser
Journal:  Semin Cell Dev Biol       Date:  2021-01-06       Impact factor: 7.499

9.  Irritable bowel syndrome and subsequent risk of Parkinson's disease: a nationwide population-based matched-cohort study.

Authors:  Mun Kyung Sunwoo; Yong Wook Kim; Seo Yeon Yoon; Jaeyong Shin; Seok-Jae Heo; Jee Suk Chang
Journal:  J Neurol       Date:  2021-07-13       Impact factor: 4.849

10.  Characterization of terminal-ileal and colonic Crohn's disease in treatment-naïve paediatric patients based on transcriptomic profile using logistic regression.

Authors:  Ilkyu Park; Jaeeun Jung; Sugi Lee; Kunhyang Park; Jea-Woon Ryu; Mi-Young Son; Hyun-Soo Cho; Dae-Soo Kim
Journal:  J Transl Med       Date:  2021-06-07       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.